However, current guidelines endorse the use of ACEIs, ARB, and beta-blockers for the primary prevention of HF in high- and very high-risk patients receiving cardiotoxic targeted cancer therapies (VEGF inhibitors, RAF/MEK inhibitors, PI, dasatinib, ponatinib, and osimertinib) with a class IIA level of evidence C. In the same context, statins have class IIA level of evidence C [31]. The gene discussed is VEGFA; the disease is hydrops fetalis.